|
|
Cardiovascular Exchange Summit 2011
|
|
|
|
|
Assess bleeding risk
|
|
|
|
Limitations of current anticoagulants
|
|
|
|
Desirable qualities of a new anticoagulant
|
|
|
|
The coagulation cascade
|
|
|
|
The role of thrombin in coagulation
|
|
|
|
Ximelagatran
|
|
|
|
RE-LY: study design
|
|
|
|
RE-LY: A Non-inferiority Trial
|
|
|
|
Trial Execution
|
|
|
|
Baseline Characteristics
|
|
|
|
Permanent Discontinuation
|
|
|
|
Stroke or Systemic Embolism
|
|
|
|
Conclusions
|
|
|
|
Conclusions
|
|
|
|
Dabigatran (D) is an alternative to VKA therapy
|
|
|
|
New Anti-Coagulants
|
|
|
|
Program of anti-Fxa in Afib
|
|
|
|
AVERROES design
|
|
|
|
apixaban
|
|
|
|
ROCKET AF Study design
|
|
|
|
ROCKET AF Primary Efficacy outcome
|
|
|
|
ROCKET AF outcome
|
|
|
|
New anti-thrombotic drugs in atrial-fibrillation Factor II en Xa inhibitors are on their way!
|
|
|
|
Clopidogrel Trials – ACS/CAD
|
|
|
|
Balance of Hemostasis and Thrombosis
|
|
|
|
Aspirin and P2Y12 ADP Antagonists: Mechanisms of Action
|
|
|
|
Clopidogrel resistance and ST
|
|
|
|
High on-treatment platelet reactivity
|
|
|
|
CLOVIS-2
|
|
|
|
Antiplatelet therapy in ACS:New agents P2Y12 inhib.
|
|
|
|
DISPERSE2 substudy in patients on chronic clopidogrel treatment
|
|
|
|
PLATO Study Design
|
|
|
|
PLATO: Efficacy and safety
|
|
|
|
TRITON-TIMI 38 Study Design
|
|
|
|
TRITON TIMI-38 overall efficacy and safety results
|
|
|
|
TRILOGY-ACS Trial Design
|
|
|
|
Updated 2011 recommendations for oral antiplatelet therapy in myocardial revascularisation: NSTE-ACS
|
|
|
|
Aspirin and P2Y12 ADP Antagonists: Mechanisms of Action
|
|
|
|
Background
|
|
|
|
Development Strategy for Thrombin Receptor Antagonist
|
|
|
|
TRA Background
|
|
|
|
Patients with high-risk Non-ST-Segment Elevation Acute Coronary Syndrome
|
|
|
|
Antiplatelet: vorapaxar (TRA)
|
|
|
|
APPRAISE-2 Efficacy
|
|
|
|
APPRAISE-2 Safety
|
|
|
|
APPRAISE
|
|
|
|
APPRAISE
|
|
|
|
ATLAS ACS-TIMI 46
|
|
|
|
ATLAS ACS-TIMI 51 study phase III efficacy and safety study
|
|
|
|
Improving outcomes with antithrombotics in patients at risk of vascular events
|
|
Deel deze pagina met collega's en vrienden: